BioCryst Pharmaceuticals, Inc. (BCRX)
-NasdaqGS | Prev Close: | 1.71 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 3.13 |
|---|
| Beta: | 2.08 |
|---|
| Next Earnings Date: | 6-Aug-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 1.08 - 4.95 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 1,469,230 |
|---|
| Market Cap: | 90.88M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.74 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- BIOCRYST PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Fri, May 17)
- Spectrum Pharma Reports 1Q LossZacks(Tue, May 14)
- BioCryst to Present at Two Upcoming Investor ConferencesBusiness Wire(Thu, May 9)
- BIOCRYST PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, May 9)
- BioCryst Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Tue, May 7)
- BioCryst Pharmaceuticals Earnings: Here’s Why the Stock is Rising Nowat Wall St. Cheat Sheet(Tue, May 7)
- Q1 2013 BioCryst Pharmaceuticals Earnings Release - Before Market OpenCCBN(Tue, May 7)
- BioCryst Provides Corporate Update and Reports First Quarter 2013 Financial ResultsBusiness Wire(Tue, May 7)
- BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD DisclosEDGAR Online(Tue, May 7)
- 5 Stocks Under $10 Set to Surgeat TheStreet(Thu, May 2)
- 5 Health Care Stocks Under $10 to Watchat TheStreet(Tue, Apr 30)
- BioCryst Heats Up: H7N9 Virus Hits Taiwan, Fatalities Up Nearly 300%at Seeking Alpha(Thu, Apr 25)
- Today's Market News To Trade On: 5 Stocks Moving On Newsat Seeking Alpha(Thu, Apr 25)
- BioCryst to Announce First Quarter 2013 Financial Results May 7Business Wire(Tue, Apr 23)
- Taiwan Warily Eyes Spread Of H7N9 In Mainland Chinaat Forbes(Thu, Apr 18)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 5.16 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.45 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.13 |
|---|
| Mean Recommendation*: | 2.8 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops novel drugs that block key enzymes involved in the pathogenesis of diseases.
View More